No Data
No Data
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersNexalin Technology (NASDAQ:NXL) stock increased by 48.1% to $1.54 during Wednesday's after-market session. The company's market cap stands at $11.4 million. Tempest Therapeutics (NASDAQ:TPST) s
Express News | Castle Biosciences’ Founder, President and CEO Derek Maetzold Named an Ey Entrepreneur of the Year® 2024 Gulf South Award Winner
Here's Why Castle Biosciences (NASDAQ:CSTL) Can Manage Its Debt Despite Losing Money
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' When we think about how
Castle Biosciences(CSTL.US) Officer Sells US$148.27K in Common Stock
$Castle Biosciences(CSTL.US)$ Officer MAETZOLD DEREK J sold 6,336 shares of common stock on Jun 3, 2024 at an average price of $23.402 for a total value of $148.27K.Source: Announcement What is statem
Form 144 | Castle Biosciences(CSTL.US) Officer Proposes to Sell 148.26K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 3, $Castle Biosciences(CSTL.US)$ Officer Derek Maetzold intends to sell 6,336 shares of its common stock on Jun 3, with a total market value of approximately $148.26K. De
Castle Biosciences to Present New Data at 2024 ASCO Annual Meeting Highlighting Use of DecisionDx-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Metastasis to the Central Nervous System to Prompt Use of Imaging Surveillance
Castle to present a second poster on its DecisionDx-UM test sharing data from an ongoing prospective, multi-center study of patients with uveal melanoma (UM) led by the Collaborative Ocular Oncology Group
No Data